<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079586</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-BIV-02-06</org_study_id>
    <secondary_id>EVOLUTION-On</secondary_id>
    <nct_id>NCT00079586</nct_id>
  </id_info>
  <brief_title>Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)</brief_title>
  <official_title>A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that in patients undergoing coronary artery&#xD;
      bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac&#xD;
      surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with&#xD;
      protamine reversal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Coronary Artery Bypass Surgery</condition>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>unfractionated heparin will be administered as per institutional practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiomax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Unfractionated Heparin per institutional practice</description>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion</description>
    <arm_group_label>Angiomax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Provide written informed consent before initiation of any study related procedures.&#xD;
&#xD;
          -  Be at least 18 years of age.&#xD;
&#xD;
          -  Be scheduled for CABG, CABG and single valve surgery, or isolated single valve surgery&#xD;
             on CPB. Patients undergoing repeat (redo) CABG are also considered eligible for this&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Confirmed pregnancy at time of randomization via IVRS (if woman of child-bearing&#xD;
             potential) (Urine or serum pregnancy test)&#xD;
&#xD;
          -  Cerebrovascular accident within 6 months, or any cerebrovascular accident with a&#xD;
             residual neurological deficit.&#xD;
&#xD;
          -  Intracranial neoplasm, arteriovenous malformation or aneurysm.&#xD;
&#xD;
          -  Dependency on renal dialysis or creatinine clearance &lt;30 mL/min.&#xD;
&#xD;
          -  Ongoing treatment with warfarin (or other oral anticoagulant) at the time of&#xD;
             randomization.&#xD;
&#xD;
        Patients previously treated with warfarin may be enrolled if warfarin therapy can be safely&#xD;
        discontinued and baseline INR is &lt; 1.3 times control in the absence of heparin therapy.&#xD;
&#xD;
          -  Known allergy to Angiomax or hirudin-derived drugs, or known sensitivity to any&#xD;
             component of the product.&#xD;
&#xD;
          -  Patients receiving clopidogrel (Plavix®) within the previous 5 days of randomization&#xD;
&#xD;
          -  Patients receiving a glycoprotein IIb/IIIa inhibitor within the previous 48 hours if&#xD;
             abciximab (ReoPro®) or 24 hours if eptifibatide (Integrilin®) or tirofiban&#xD;
             (Aggrastat®) of randomization.&#xD;
&#xD;
          -  Patients receiving lepirudin (Refludan®) or argatroban within the previous 24 hours&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Patients receiving LMWH or thrombolytics within the previous 12 hours or&#xD;
             unfractionated heparin within 30 minutes of randomization.&#xD;
&#xD;
          -  Participation in other clinical research studies involving the evaluation of other&#xD;
             investigational drugs or devices within 30 days of randomization.&#xD;
&#xD;
          -  Refusal to undergo blood transfusion should it become necessary.&#xD;
&#xD;
          -  Any other disease or condition, which, in the judgment of the Investigator, would&#xD;
             place a patient at undue risk by being enrolled in the trial, or cause inability to&#xD;
             comply with the trial.&#xD;
&#xD;
          -  Planned surgical procedure in which proximal anastomoses will precede distal&#xD;
             anastomoses of the bypass grafts.&#xD;
&#xD;
          -  Planned (&gt;1) double (or greater) valve repair-replacement (e.g.: AVR-MVR) surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Lloyd, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Medicines Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>March 9, 2004</study_first_submitted>
  <study_first_submitted_qc>March 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2004</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

